Fennec Banks On EMA’s Seldom-Used PUMA For Sodium Thiosulfate
Executive Summary
Fennec Pharmaceuticals says that its new formulation of sodium thiosulfate for preventing cisplatin-induced hearing loss in children targets a critical unmet medical need.
You may also be interested in...
Fennec Prepared For Market As Pedmark Finally Gets FDA Nod
After successive CRLs in 2020 and 2021, the drug gained a broad label for hearing loss in children treated with cisplatin for localized, non-metastatic solid tumors.
Novel Combined Contraceptive Estelle Among Nine New Filings At EMA
Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."
Novel Combined Contraceptive Estelle Among Nine New Filings At EMA
Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."